China Active Pharmaceutical Ingredients (API) Market Size (2024 - 2029)

The market size of the Chinese Active Pharmaceutical Ingredients (API) sector is anticipated to experience significant growth over the forecast period. This expansion is driven by the resumption of import-export activities, increased production to meet global demands, and the rising prevalence of chronic and infectious diseases, which boost the need for advanced medications. The growing geriatric population and the development of new-generation drugs also contribute to the market's growth. Additionally, strategic business activities and the construction of new manufacturing facilities further support the market's expansion. However, stringent drug approval regulations and pricing policies may pose challenges to this growth.

Market Size of China Active Pharmaceutical Ingredients (API) Industry

China Active Pharmaceutical Ingredients (API) Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 14.81 Billion
Market Size (2029) USD 21.62 Billion
CAGR (2024 - 2029) 7.86 %
Market Concentration Medium

Major Players

China Active Pharmaceutical Ingredients (API) Market Major Players

*Disclaimer: Major Players sorted in no particular order

China Active Pharmaceutical Ingredients (API) Market Analysis

The China Active Pharmaceutical Ingredients Market size is estimated at USD 14.81 billion in 2024, and is expected to reach USD 21.62 billion by 2029, growing at a CAGR of 7.86% during the forecast period (2024-2029).

The market is expected to grow due to the increasing prevalence of chronic disorders and the rising adoption and approval of biologics and biosimilars during the forecast period.

The increasing prevalence and incidence of chronic diseases, infectious diseases, and genetic disorders in China are driving the demand for effective and safe drugs. Thus, the need for active pharmaceutical ingredients across the country is increasing for the development of novel drugs for various diseases. This, in turn, is further expected to fuel the growth of the active pharmaceutical ingredients market during the forecast period. For instance, according to an article published in the Chinese Medical Journal in March 2022, it has been observed that about 4.82 million new cancer cases were diagnosed in China in 2022, compared to 4.5 million cases in the last year. Thus, the expected increase in the number of people who have cancer, including colorectal cancer, raises the demand for novel drugs for the treatment. This, in turn, is anticipated to propel the growth of the APIs market during the forecast period.

Also, ischemic heart disease, stroke, Alzheimer’s and other dementias, and chronic obstructive pulmonary disease are the four most frequent causes of disability-adjusted life years among the population. For instance, according to an article published in BMC Public Health in June 2023, it was observed that about 40 million people living in China are expected to suffer from Alzheimer’s disease and related dementias by 2050. Thus, the expected increase in the patient population raises the need to develop novel biological drugs, which is expected to increase the demand for APIs in China.

Moreover, the increasing adoption and approval of biologics and biosimilars are expected to drive the market during the forecast period. Healthcare systems worldwide actively seek ways to lower costs and raise revenues. Innovative formulary management provides a way to save prescription prices without sacrificing patient care. Specialty pharmaceuticals are one prominent area in which cost reductions would make a significant difference because of the high cost of biologics, which results in a disproportionate contribution to the total national drug spending. Thus, using less expensive biosimilars offers a chance to reduce drug costs and spending on biologics without compromising patient outcomes.

For instance, according to an article published in Health Policy in October 2023, it was observed that the cost of cancer biosimilars was 69% to 90% of the costs for the reference drugs, and their uptake reached 54% to 83% in China in 2022. Hence, biosimilars' lower cost and clinical benefits are expected to increase their adoption, ultimately driving the market during the forecast period. Similarly, in an article published in Bioengineered in June 2022, the Chinese researchers observed that biosimilar monoclonal antibodies are one of the hotspots of research and development in China, with continuous improvement of policies and increasing interest in research and development of biosimilars.

Thus, owing to the development of biopharmaceuticals markets, the demand for biosimilars in China is expected to grow gradually, with the improvement of the national guidelines, further increasing its adoption for the treatment of various chronic and infectious disorders, contributing to the market growth.

Therefore, the market is expected to grow during the forecast period due to the aforementioned factors, such as the increasing prevalence of chronic diseases and the increasing adoption and approval of biologics and biosimilars. However, the country's stringent regulations for drug approvals and drug price policies are expected to hinder market growth during the forecast period.

China Active Pharmaceutical Ingredients (API) Industry Segmentation

As per the scope of the report, an active pharmaceutical ingredient (API) is a part of any drug that produces its effects. Some drugs, such as combination therapies, have multiple active ingredients to treat symptoms or act differently. They are produced using highly technological industrial processes during the R&D and commercial production phases. The Chinese active pharmaceutical ingredients (API) market is segmented by business mode, type of drug, and application. By business mode, the market is segmented into captive API and merchant API. By drug type, the market is segmented into generic and branded. By synthetic type, the market is segmented into synthetic and biotech, and by application, the market is segmented into cardiology, oncology, pulmonology, neurology, orthopedics, ophthalmology, and other applications. The report offers the value (USD) for the above segments.

By Business Mode
Captive API
Merchant API
By Synthesis Type
Synthetic
Biotech
By Drug Type
Generic
Branded
By Application
Cardiology
Oncology
Pulmonology
Neurology
Orthopedic
Ophthalmology
Other Applications
Need A Different Region Or Segment?
Customize Now

China Active Pharmaceutical Ingredients (API) Market Size Summary

The Chinese Active Pharmaceutical Ingredients (API) market is poised for significant growth, driven by a combination of factors including the rising prevalence of chronic and infectious diseases, advancements in oncology drug research, and an expanding geriatric population. The market experienced disruptions during the COVID-19 pandemic, which affected the supply chain and led to shortages and price increases for certain APIs. However, with the resumption of import-export activities and the lifting of restrictions, the market is expected to recover and expand. China's role as a major supplier of APIs, particularly to the United States, underscores its importance in the global pharmaceutical landscape. The country's focus on enhancing API production capabilities is anticipated to meet the growing international demand, further propelling market growth.

The market is characterized by a fragmented landscape with numerous manufacturers engaging in strategic collaborations, facility expansions, and product approvals to strengthen their market presence. The oncology segment is expected to witness substantial growth due to the increasing incidence of cancer and the corresponding demand for effective cancer treatments. Additionally, the high burden of chronic diseases, such as diabetes and cardiovascular conditions, particularly among the aging population, is driving the demand for APIs in drug development. Companies are actively expanding their manufacturing facilities to accommodate this demand, with notable investments in high-potency API production. Despite challenges posed by stringent regulatory frameworks, the market is set to grow, supported by ongoing industry activities and the increasing need for advanced pharmaceuticals.

Explore More

China Active Pharmaceutical Ingredients (API) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Chronic Disorders

      2. 1.2.2 Increasing Adoption and Approval of Biologicals and Biosimilars

    3. 1.3 Market Restraints

      1. 1.3.1 Drug Price Control Policies

      2. 1.3.2 High Competition Between API Manufacturers and Stringent Regulations

    4. 1.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Business Mode

      1. 2.1.1 Captive API

      2. 2.1.2 Merchant API

    2. 2.2 By Synthesis Type

      1. 2.2.1 Synthetic

      2. 2.2.2 Biotech

    3. 2.3 By Drug Type

      1. 2.3.1 Generic

      2. 2.3.2 Branded

    4. 2.4 By Application

      1. 2.4.1 Cardiology

      2. 2.4.2 Oncology

      3. 2.4.3 Pulmonology

      4. 2.4.4 Neurology

      5. 2.4.5 Orthopedic

      6. 2.4.6 Ophthalmology

      7. 2.4.7 Other Applications

China Active Pharmaceutical Ingredients (API) Market Size FAQs

The China Active Pharmaceutical Ingredients Market size is expected to reach USD 14.81 billion in 2024 and grow at a CAGR of 7.86% to reach USD 21.62 billion by 2029.

In 2024, the China Active Pharmaceutical Ingredients Market size is expected to reach USD 14.81 billion.

China Active Pharmaceutical Ingredients (api) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)